Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.

The biopharmaceutical company recently filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, providing flexibility to issue common and preferred stock, debt, warrants and units. This expanded financing capacity comes as Corvus continues to run multiple clinical trials for its lead candidate soquelitinib across dermatology, pulmonary medicine, rheumatology and oncology indications.

Investors appear concerned about potential "value destructive dilution" as the company, which reported a US$15.28 million net loss for full year 2025 and has no product revenue, may need to raise additional capital through equity issuance to fund its ongoing clinical programs. The expanded ATM facility increases the risk of share dilution for existing shareholders, particularly if the company leans heavily on this financing option ahead of key clinical readouts for soquelitinib.